News
Simulations Plus, Inc. (SLP) Q2 2025 Earnings Call Transcript
Simulations Plus, Inc. (NASDAQ:SLP ) Q2 2025 Earnings Conference Call April 3, 2025 5:00 PM ET Company Participants Lisa Fortuna - IR, Financial Profiles Shawn O'Connor - CEO Will Frederick - CFO & COO Conference Call Participants David Larsen - BTIG Scott Schoenhaus - KeyBanc Capital Markets Matt Hewitt - Craig-Hallum Christine Rains - William Blair Jeff Garro - Stephens Constantine Davies - Citizen Operator Greetings, and welcome to the Simulations Plus Second Quarter Fiscal 2025 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
seekingalpha.com • Apr 03, 2025 20:44 Eastern
Simulations Plus (SLP) Tops Q2 Earnings and Revenue Estimates
Simulations Plus (SLP) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.20 per share a year ago.
zacks.com • Apr 03, 2025 18:21 Eastern
Simulations Plus Reports Second Quarter Fiscal 2025 Financial Results
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its second quarter fiscal 2025, ended February 28, 2025. Second Quarter 2025 Financial Highlights (as compared to second quarter 2024) Total revenue increased 23% to $22.4 million Software.
businesswire.com • Apr 03, 2025 16:05 Eastern
Simulations Plus Gears Up for Q2 Earnings: What's in the Offing?
SLP's fiscal Q2 2025 performance is likely to have benefited from continued momentum across its Software and Services segments amid budget constraints.
zacks.com • Apr 01, 2025 10:05 Eastern
Simulations Plus Announces Second Quarter Fiscal Year 2025 Earnings and Conference Call Date
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it will report second quarter fiscal 2025 financial results after the market close on Thursday, April 3, 2025. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discu.
businesswire.com • Mar 20, 2025 07:00 Eastern
Simulations Plus to Present at the KeyBanc Capital Markets Virtual Healthcare Investor Forum
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that Shawn O'Connor, Chief Executive Officer, will be participating in a fireside chat at the KeyBanc Capital Markets Virtual Healthcare Investor Forum on Tuesday, March 18, 2025, at 2:15 p.m. Eastern Ti.
businesswire.com • Mar 10, 2025 07:00 Eastern
Simulations Plus to Participate in Upcoming Healthcare Investor Conferences
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it will participate in two healthcare investor conferences in February. The Company is attending the BTIG 12th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference taking p.
businesswire.com • Feb 04, 2025 07:30 Eastern
Simulations Plus and Enabling Technologies Consortium Announce Strategic Collaboration to Advance GastroPlus® Enhancements
RESEARCH TRIANGLE, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it has entered a new funded collaboration with the Enabling Technologies Consortium (ETC). This partnership is aimed at advancing in vitro-in vivo correlation (IVIVC) approaches for oral drug delivery and expanding the function.
businesswire.com • Jan 22, 2025 07:50 Eastern